The 2031 upside depends on proving that recurring enterprise workflow (and eventually guided-scanning + AI attach) can outgrow device cycles while gross margin volatility is eliminated. If those gates clear, a higher-quality revenue mix supports a multi-year re-rate; if not, dilution and bundling pressure cap returns.

If Butterfly executes the shift from device-led sales to enterprise workflow + guided-scanning + attachable AI modules (and fixes inventory/COGS volatility), it can compound into a recurring “ultrasound operating layer,” supporting a durable re-rate from niche handheld hardware toward a small-cap platform-medtech multiple by 2031.

AI makes clinical cognition cheaper; Butterfly benefits by turning bedside ultrasound into repeatable, software-mediated workflows (guidance, QA, reporting, provenance) and by monetizing data/semiconductor licensing—if it earns trust and proves unit economics at scale.

The upside case is a mix shift: more enterprise-standard deployments where software becomes embedded (single sign-on, worklists, reporting, storage) and where guided scanning/QA unlocks new non-expert user segments. If Butterfly shows repeatable enterprise ROI, stabilizes gross margin by eliminating inventory obsolescence shocks, and lands even a couple of credible co-development / chip-licensing relationships, investors can underwrite recurring revenue durability and assign a higher-quality medtech/software multiple versus a commodity handheld device maker.

The key risk is a timing trap: enterprise adoption and AI/workflow monetization may arrive slower than cash burn and inventory/COGS shocks, forcing dilution. If incumbents win procurement via bundling, Butterfly’s bargaining power drops and it stays a lower-multiple device category.

$4.38